In the real world, the detection rates of PDL1 expression and mismatch repair status in G/GEJ adenocarcinoma patients are much lower than those in RCTs with strict enrollment criteria, possibly due to reasons such as limited biopsy specimen slices not meeting the needs of multiple immunohistochemical tests, and resistance to re-biopsy by patients. The gene discussed is CD274; the disease is adenocarcinoma.